The Market Reports

Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com

Antidiabetic SGLT-2 Inhibitor-Global Market Insights and Sales Trends 2024

Antidiabetic SGLT-2 Inhibitor-Global Market Insights and Sales Trends 2024

Publishing Date : Dec, 2023

License Type :
 

Report Code : 1840247

No of Pages : 105

Ask Your Query
Synopsis
The global Antidiabetic SGLT-2 Inhibitor market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Antidiabetic SGLT-2 Inhibitor in various end use industries. The expanding demands from the Hospitals, Clinics and Other, are propelling Antidiabetic SGLT-2 Inhibitor market. Canagliflozin, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Empagliflozin segment is estimated at % CAGR for the next seven-year period.
According to the Global Use of Medicines 2023 released by IQVIA Institute, the global drug expenditure in 2022 was about US$1.48 trillion (excluding COVID vaccine and treatment-related expenses), and it is predicted to grow at a rate of 3%-6% in the next few years. In terms of drug expenditure, this number in China was about 166 billion dollars in 2022. It is expected that the expenditure on medicines will increase in the next few years. From the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines.
Global Use of Medicines 2023 shows that the U.S. market spent about US$ 62.9 billion on medicines in 2022 on a net ex-factory basis. Overall growth slows as the Inflation Reduction Act (IRA) spends US$64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years. Besides, ex-factory discounts and rebates in drug distribution, the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Antidiabetic SGLT-2 Inhibitor, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Antidiabetic SGLT-2 Inhibitor market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Antidiabetic SGLT-2 Inhibitor market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Antidiabetic SGLT-2 Inhibitor sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Antidiabetic SGLT-2 Inhibitor covered in this report include Pfizer, AstraZeneca, Johnson & Johnson, GlaxoSmithKline, Merck & Co, Eli Lilly, Sanofi, Takeda Pharmaceuticals and Novo Nordisk, etc.
The global Antidiabetic SGLT-2 Inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Pfizer
AstraZeneca
Johnson & Johnson
GlaxoSmithKline
Merck & Co
Eli Lilly
Sanofi
Takeda Pharmaceuticals
Novo Nordisk
Servier Laboratories
Boehringer Ingelheim
Bristol-Myers Squibb
Global Antidiabetic SGLT-2 Inhibitor market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Antidiabetic SGLT-2 Inhibitor market, Segment by Type:
Canagliflozin
Empagliflozin
Dapagliflozin
Other
Global Antidiabetic SGLT-2 Inhibitor market, by Application
Hospitals
Clinics
Other
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Antidiabetic SGLT-2 Inhibitor manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Antidiabetic SGLT-2 Inhibitor in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index
1 Antidiabetic SGLT-2 Inhibitor Market Overview
1.1 Antidiabetic SGLT-2 Inhibitor Product Overview
1.2 Antidiabetic SGLT-2 Inhibitor Market Segment by Type
1.2.1 Canagliflozin
1.2.2 Empagliflozin
1.2.3 Dapagliflozin
1.2.4 Other
1.3 Global Antidiabetic SGLT-2 Inhibitor Market Size by Type
1.3.1 Global Antidiabetic SGLT-2 Inhibitor Market Size Overview by Type (2018-2029)
1.3.2 Global Antidiabetic SGLT-2 Inhibitor Historic Market Size Review by Type (2018-2023)
1.3.3 Global Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Type (2018-2023)
1.4.2 Europe Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Type (2018-2023)
2 Global Antidiabetic SGLT-2 Inhibitor Market Competition by Company
2.1 Global Top Players by Antidiabetic SGLT-2 Inhibitor Sales (2018-2023)
2.2 Global Top Players by Antidiabetic SGLT-2 Inhibitor Revenue (2018-2023)
2.3 Global Top Players by Antidiabetic SGLT-2 Inhibitor Price (2018-2023)
2.4 Global Top Manufacturers Antidiabetic SGLT-2 Inhibitor Manufacturing Base Distribution, Sales Area, Product Type
2.5 Antidiabetic SGLT-2 Inhibitor Market Competitive Situation and Trends
2.5.1 Antidiabetic SGLT-2 Inhibitor Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Antidiabetic SGLT-2 Inhibitor Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Antidiabetic SGLT-2 Inhibitor as of 2022)
2.7 Date of Key Manufacturers Enter into Antidiabetic SGLT-2 Inhibitor Market
2.8 Key Manufacturers Antidiabetic SGLT-2 Inhibitor Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Antidiabetic SGLT-2 Inhibitor Status and Outlook by Region
3.1 Global Antidiabetic SGLT-2 Inhibitor Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Antidiabetic SGLT-2 Inhibitor Historic Market Size by Region
3.2.1 Global Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region (2018-2023)
3.2.2 Global Antidiabetic SGLT-2 Inhibitor Sales in Value by Region (2018-2023)
3.2.3 Global Antidiabetic SGLT-2 Inhibitor Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Region
3.3.1 Global Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region (2024-2029)
3.3.2 Global Antidiabetic SGLT-2 Inhibitor Sales in Value by Region (2024-2029)
3.3.3 Global Antidiabetic SGLT-2 Inhibitor Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Antidiabetic SGLT-2 Inhibitor by Application
4.1 Antidiabetic SGLT-2 Inhibitor Market Segment by Application
4.1.1 Hospitals
4.1.2 Clinics
4.1.3 Other
4.2 Global Antidiabetic SGLT-2 Inhibitor Market Size by Application
4.2.1 Global Antidiabetic SGLT-2 Inhibitor Market Size Overview by Application (2018-2029)
4.2.2 Global Antidiabetic SGLT-2 Inhibitor Historic Market Size Review by Application (2018-2023)
4.2.3 Global Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Application (2018-2023)
4.3.2 Europe Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales Breakdown by Application (2018-2023)
5 North America Antidiabetic SGLT-2 Inhibitor by Country
5.1 North America Antidiabetic SGLT-2 Inhibitor Historic Market Size by Country
5.1.1 North America Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2018-2023)
5.1.3 North America Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2018-2023)
5.2 North America Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Country
5.2.1 North America Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2024-2029)
5.2.2 North America Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2024-2029)
6 Europe Antidiabetic SGLT-2 Inhibitor by Country
6.1 Europe Antidiabetic SGLT-2 Inhibitor Historic Market Size by Country
6.1.1 Europe Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2018-2023)
6.1.3 Europe Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2018-2023)
6.2 Europe Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Country
6.2.1 Europe Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2024-2029)
6.2.2 Europe Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2024-2029)
7 Asia-Pacific Antidiabetic SGLT-2 Inhibitor by Region
7.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Historic Market Size by Region
7.1.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Region
7.2.1 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Antidiabetic SGLT-2 Inhibitor Sales in Value by Region (2024-2029)
8 Latin America Antidiabetic SGLT-2 Inhibitor by Country
8.1 Latin America Antidiabetic SGLT-2 Inhibitor Historic Market Size by Country
8.1.1 Latin America Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2018-2023)
8.1.3 Latin America Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2018-2023)
8.2 Latin America Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Country
8.2.1 Latin America Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2024-2029)
8.2.2 Latin America Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2024-2029)
9 Middle East and Africa Antidiabetic SGLT-2 Inhibitor by Country
9.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Historic Market Size by Country
9.1.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Forecasted Market Size by Country
9.2.1 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Antidiabetic SGLT-2 Inhibitor Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Pfizer
10.1.1 Pfizer Company Information
10.1.2 Pfizer Introduction and Business Overview
10.1.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Pfizer Antidiabetic SGLT-2 Inhibitor Products Offered
10.1.5 Pfizer Recent Development
10.2 AstraZeneca
10.2.1 AstraZeneca Company Information
10.2.2 AstraZeneca Introduction and Business Overview
10.2.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.2.4 AstraZeneca Antidiabetic SGLT-2 Inhibitor Products Offered
10.2.5 AstraZeneca Recent Development
10.3 Johnson & Johnson
10.3.1 Johnson & Johnson Company Information
10.3.2 Johnson & Johnson Introduction and Business Overview
10.3.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.3.4 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Products Offered
10.3.5 Johnson & Johnson Recent Development
10.4 GlaxoSmithKline
10.4.1 GlaxoSmithKline Company Information
10.4.2 GlaxoSmithKline Introduction and Business Overview
10.4.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.4.4 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Products Offered
10.4.5 GlaxoSmithKline Recent Development
10.5 Merck & Co
10.5.1 Merck & Co Company Information
10.5.2 Merck & Co Introduction and Business Overview
10.5.3 Merck & Co Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Merck & Co Antidiabetic SGLT-2 Inhibitor Products Offered
10.5.5 Merck & Co Recent Development
10.6 Eli Lilly
10.6.1 Eli Lilly Company Information
10.6.2 Eli Lilly Introduction and Business Overview
10.6.3 Eli Lilly Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Eli Lilly Antidiabetic SGLT-2 Inhibitor Products Offered
10.6.5 Eli Lilly Recent Development
10.7 Sanofi
10.7.1 Sanofi Company Information
10.7.2 Sanofi Introduction and Business Overview
10.7.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Sanofi Antidiabetic SGLT-2 Inhibitor Products Offered
10.7.5 Sanofi Recent Development
10.8 Takeda Pharmaceuticals
10.8.1 Takeda Pharmaceuticals Company Information
10.8.2 Takeda Pharmaceuticals Introduction and Business Overview
10.8.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Products Offered
10.8.5 Takeda Pharmaceuticals Recent Development
10.9 Novo Nordisk
10.9.1 Novo Nordisk Company Information
10.9.2 Novo Nordisk Introduction and Business Overview
10.9.3 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Novo Nordisk Antidiabetic SGLT-2 Inhibitor Products Offered
10.9.5 Novo Nordisk Recent Development
10.10 Servier Laboratories
10.10.1 Servier Laboratories Company Information
10.10.2 Servier Laboratories Introduction and Business Overview
10.10.3 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.10.4 Servier Laboratories Antidiabetic SGLT-2 Inhibitor Products Offered
10.10.5 Servier Laboratories Recent Development
10.11 Boehringer Ingelheim
10.11.1 Boehringer Ingelheim Company Information
10.11.2 Boehringer Ingelheim Introduction and Business Overview
10.11.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.11.4 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Products Offered
10.11.5 Boehringer Ingelheim Recent Development
10.12 Bristol-Myers Squibb
10.12.1 Bristol-Myers Squibb Company Information
10.12.2 Bristol-Myers Squibb Introduction and Business Overview
10.12.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Revenue and Gross Margin (2018-2023)
10.12.4 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Products Offered
10.12.5 Bristol-Myers Squibb Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Antidiabetic SGLT-2 Inhibitor Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Antidiabetic SGLT-2 Inhibitor Industrial Chain Analysis
11.4 Antidiabetic SGLT-2 Inhibitor Market Dynamics
11.4.1 Antidiabetic SGLT-2 Inhibitor Industry Trends
11.4.2 Antidiabetic SGLT-2 Inhibitor Market Drivers
11.4.3 Antidiabetic SGLT-2 Inhibitor Market Challenges
11.4.4 Antidiabetic SGLT-2 Inhibitor Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Antidiabetic SGLT-2 Inhibitor Distributors
12.3 Antidiabetic SGLT-2 Inhibitor Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer

Published By : QY Research

Why ‘The Market Reports’

In Business: Pre Sales Support: Post Sales Support: Turn Around Time: Clients Served: Clients Assisted: Client Types: Payment: Partners with: Number of reports: Custom Research: Report Availability: Report Delivery Format: Security:

Payments Accepted From

Connect with us at

Complete Secure Website

SiteLock